Cutaneous squamous cell carcinoma

SummaryCutaneous squamous cell carcinoma (cSCC) accounts for approximately 20% of all skin cancers. Its rising incidence represents a major public health concern. The majority of cSCC are curable by surgical resection. Although less than 5% of cSCC patients develop metastases or local recurrence after complete excision, advanced cSCC is difficult to treat. Until recently, no standard therapeutic regimen for advanced cSCC exists. Traditional therapies include chemotherapy and EGFR-targeted therapy, but their clinical benefit remains modest and has been demonstrated mostly in retrospective studies. On the contrary, PD-1 inhibitors dramatically improve outcomes in many immunocompetent cSCC patients, resulting in the approval of cemiplimab as the first FDA-approved systemic drug for patients with locally advanced or metastatic cSCC who are not candidates for curative surgery or radiation. In the coming years combination therapies are an emerging treatment strategy that could improve efficacy of PD-1 inhibitors in advanced cSCC. Moreover, several prospective controlled trials have been designed to explore the potential role of PD-1 inhibitors in the adjuvant and neodjuvant setting. Given the paucity of data, the management of immunocompromised cSCC patients requires a heightened awareness in this new era of cancer therapeutics.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSION: Induction chemotherapy with Cisplatin and Docetaxel is a promising regimen with good response and favorable toxicity profile and can be considered as a potentially effective outpatient regimen for locally advanced squamous cell carcinoma of head and neck. PMID: 32212813 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Somatic alterations in the epidermal growth factor receptor gene (EGFR) result in aberrant activation of kinase signaling and occur in ∼15% of non-small cell lung cancers (NSCLC). Patients diagnosed with EGFR-mutant NSCLC have good initial clinical response to EGFR tyrosine kinase inhibitors (EGFR TKIs), yet tumor recurrence is common and quick to develop. Mechanisms of acquired resistance to EGFR TKIs have been studied extensively over the past decade. Great progress has been made in understanding two major routes of therapeutic failure: additional genomic alterations in the EGFR gene and activation of alternative kin...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
In this study, we investigated the utility of miR-3692-3p, miR-3195, and miR-1249-3p as biomarkers in non-small cell lung cancer (NSCLC). For this prospective study, 115 subjects, including 75 NSCLC patients and 40 controls, were recruited. The expression of miR-3692-3p, miR-3195, and miR-1249-3p was checked using qRT-PCR. The miRNA expression was correlated with survival outcome and therapeutic response. There were no significant differences in the mean age of NSCLC patients and controls (56.2 and 55.3  years, respectively;p = 0.3242). Majority of NSCLC patients (67%) were smokers. We observed a signifi...
Source: Human Cell - Category: Cytology Source Type: research
AbstractBackgroundThe optimal radiation field of chemoradiation therapy (CRT) for stage I esophageal squamous cell carcinoma (ESCC) is unknown. This retrospective study compared efficacy and safety of two CRT modalities, involved field irradiation (IFI) and elective nodal irradiation (ENI), when treating patients with clinical stage I (T1bN0M0) ESCC.MethodsPatients had received 60  Gy CRT concurrently with 5-FU and cisplatin between January 2000 and December 2012. The clinical target volume of IFI was limited to the primary tumor plus a 2-cm craniocaudal margin; that of ENI covered the primary tumor plus the field of ...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundPoor oral health is an independent risk factor for upper aerodigestive tract cancers, including esophageal squamous cell carcinoma (ESCC). The pattern recognition receptor Toll-like receptor 4 (TLR4) recognizes lipopolysaccharide in the cell walls of Gram-negative periodontal pathogens associated with the development and progression of ESCC. It is, therefore, plausible that TLR4 plays a crucial role in the pathogenesis of ESCC.MethodsWe used an ESCC tissue microarray to confirm expression of TLR4 in patients with ESCC and to determine whether TLR4 expression status correlates with the clinicopathological ...
Source: Esophagus - Category: Gastroenterology Source Type: research
Esophageal squamous cell carcinoma (ESCC) is one of the most prevalent cancers worldwide. Recent studies have shown that cancer stem cells (CSCs) are present in ESCC, are thought to lead to aggressive tumor behavior and the prognosis. The CXC chemokine receptor 4 (CXCR4), is regarded as a putative CSCs marker in various malignancies. Here, we demonstrate that CXCR4 played a key role in ESCC progression and CXCR4 positive ESCC cells possessed stem-like properties. Furthermore, the anti-malarial agent chloroquine (CQ) targeted CXCR4-positive ESCC cells via STAT3 pathway. Therefore, CQ with anti-CSCs effects may be an effecti...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The aim of this ongoing study was to examine Quality of Life (QoL) and pain in the first three months after trans-oral robotic surgery (TORS). Results will be available in November 2019. With the rising incidence of Human Papilloma Virus (HPV) induced oropharyngeal squamous cell carcinoma (OPSCC) this cancer has become the most frequently diagnosed head and neck cancer world-wide. Currently there are two main treatment options: radiotherapy (with or without chemotherapy) and TORS. TORS is still a relatively new treatment modality (approved by the FDA in 2000) and more research into outcomes, particularly functional and QoL outcomes is needed.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Toxicity, Quality of Life, Survivorship, Costs of Care Source Type: research
The objective of this presentation is to report survival outcomes and treatment toxicity in patients with NPC treated with AFRT compared with CFRT as part of phase II clinical trial.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Definitive Management of Head and Neck Squamous Cell Carcinoma Source Type: research
The objectives of this retrospective study were to evaluate treatment patterns and RW outcomes of patients with mHN cancer treated in the US community setting.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Epidemiology and Prevention Source Type: research
Sinonasal squamous cell carcinoma (SNSCC) is relatively rare, accounting for less than 3% of all head and neck cancers. Despite intensive treatment, SNSCC is aggressive, with only approximately 50% of patients surviving beyond five years after diagnosis. Treatment typically involves a combination of surgery and radiation with or without cytotoxic chemotherapy, such as cisplatin. Little is known about genetic mutations that occur in SNSCC, and even less is known about potential driving mutations.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Molecular Biology and Therapeutics Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | International Medicine & Public Health | Skin | Skin Cancer | Squamous Cell Carcinoma | Study